Inflammation in the Alzheimer's Disease Cascade: Culprit or Innocent Bystander? by Seshadri, Sudha & Tan, Zaldy Sy
 
Inflammation in the Alzheimer's Disease Cascade: Culprit or
Innocent Bystander?
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Tan, Zaldy S., and Sudha Seshadri. 2010. Inflammation in the
Alzheimer's disease cascade: Culprit or innocent bystander?
Alzheimer's Research & Therapy 2(2): 6.
Published Version doi:10.1186/alzrt29
Accessed February 19, 2015 8:46:04 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:5136951
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAWhile the blood-brain barrier restricts the ﬂ  ow of blood-
borne ions, molecules, and cells into the neural tissue, 
protecting the central nervous system from insult and 
injury, it also diminishes the utility of measuring circu-
lating biomarkers to study changes that may be happen-
ing within the brain. However, peripheral blood mono-
cytes and macrophages actively cross the blood-brain 
barrier and hence may better reﬂ  ect inﬂ  ammation within 
the neuropil. Th  us, whereas three large population 
studies failed to relate circulating levels of inﬂ  ammatory 
markers, such as C-reactive protein (CRP), to risk of 
cognitive decline and clinical Alzheimer disease (AD) 
[1-3], one of these, the Framingham Study, reported an 
association between the increased production of 
cytokines (inter  leukin-1 [IL-1] and tumor necrosis 
factor-alpha) by peri  pheral blood monocytes and an 
approximately twofold increase in risk of incident AD [3].
Although late-onset AD (LOAD) in patients older than 
65 years of age appears to be strongly heritable, a sub-
stantial proportion of this heritability remains un-
explained by known genetic and environmental factors 
[4]. Th   e strongest known risk factors for LOAD remain a 
positive family history and the APOE ε4 allele. van Exel 
and colleagues [5] use these known risk factors to identify 
high- and low-risk samples of middle-aged persons in 
whom they compare levels of inﬂ  ammatory and vascular 
risk factors. In this Dutch study, they observed that 
middle-aged persons with a parental history of LOAD 
had adverse levels of certain vascular risk factors (higher 
systolic and diastolic blood pressures and a lower ankle-
brachial index) and greater production of proinﬂ  am-
matory cytokines in lipopoly  saccharide-stimulated whole 
blood samples when compared with middle-aged persons 
whose parents were known to be free of dementia. While 
the APOE ε4 allele genotype was more frequent among 
oﬀ   spring with parental AD compared with controls, 
these ﬁ  ndings were independent of APOE genotype. Th  e 
investigators did not link higher blood pressures and 
markers of inﬂ   am  mation to cognitive performance, 
neuroimaging ﬁ   ndings, or other surrogate markers of 
accelerated brain aging. Th  is and the fact that the 
participants were too young to develop clinical dementia 
due to AD (mean age of 48.9  years) limit the inter-
pretation of their study ﬁ  ndings. However, a few prior 
studies have linked peripheral inﬂ   am  mation to lower 
brain volumes, to baseline cognitive function, and to 
greater cognitive decline [6-8]. In the Framingham Study, 
among persons who had at least one APOE ε4 allele, 
veriﬁ  ed parental dementia resulted in smaller total brain 
volumes [9] and lower scores on verbal memory tasks. 
Th  us, among persons with an increased genetic risk for 
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The strongest known risk factors for late-onset 
Alzheimer disease (LOAD) remain a positive family 
history and the APOE ε4 allele. van Exel and colleagues 
used these known risk factors to identify high- and 
low-risk samples of middle-aged persons in whom 
they compared levels of infl  ammatory and vascular 
risk factors. They observed that, compared with 
controls, middle-aged off  spring of families with a 
parental history of LOAD had higher blood pressures, 
lower ankle-brachial indices (measure of peripheral 
atherosclerosis), and increased production of 
proinfl  ammatory cytokines in lipopolysaccharide-
stimulated whole blood samples, associations that 
were independent of APOE genotype. This study adds 
to the growing body of evidence linking infl  ammatory 
mechanisms to Alzheimer disease risk and, especially 
when considered in light of the recently described 
association of genetic variation in the complement 
receptor 1 (CR1) gene with LOAD, suggests that 
infl  ammatory biomarkers (whether causal or incidental) 
could be measured and perhaps used to risk-stratify 
middle-aged persons for early preventive and 
therapeutic interventions.
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genetic inﬂ   uences, one of which may be complement 
receptor 1 (CR1), a gene that could modify an individual’s 
response to inﬂ  amma  tion-inducing  environmental 
stimuli [10]. Studies have also shown that aging alone can 
cause an increase in peripheral cytokine concentrations 
[11].
Cytokine dysregulation can lead to neuronal injury 
through a variety of mechanisms, including altered 
neuro  transmission, apoptosis, and activation of microglia 
and astrocytes, which in turn lead to production of free 
radicals, complement factors, glutamate, and nitric oxide 
[12]. Postmortem studies of AD brains demonstrated the 
presence of acute-phase inﬂ  ammatory reactants (includ-
ing CRP, proinﬂ   ammatory cytokines, and activated 
complement cascade proteins) in the senile plaques and 
neuroﬁ  brillary tangles that are the pathologic hallmarks 
of AD [13,14]. Th   e concentrations of inﬂ  ammatory 
markers in these areas are intense, with levels higher than 
those seen in infarcted hearts, atherosclerotic plaques, or 
replaced joints [15]. Although it is unclear whether these 
proinﬂ  ammatory cytokines are etiopathologically involved 
in the AD cascade or are merely innocent bystanders, 
ﬁ  ndings that implicate cytokines in the expression and 
processing of β-amyloid precursor protein [16,17] and 
the promotion in turn by ﬁ   brillar β-amyloid of the 
production of proinﬂ  ammatory cytokines by microglial 
and monocytic cell lines [18] suggest that inﬂ  ammation 
may amplify several steps of the amyloid cascade. Beyond 
β-amyloid, IL-1 has been demonstrated to increase 
neuronal tau phosphorylation [19].
Initially, a number of observational population-based 
cohort studies [20] had linked intake of nonsteroidal anti-
inﬂ   ammatory drugs (NSAIDs) to a lowered risk of 
developing AD. However, a recent meta-analysis failed to 
observe any association of either the serum-amyloid 
lowering (SALA) or the non-SALA NSAIDs with a lower 
risk of AD [21]. Randomized placebo-controlled clinical 
trials also failed to demonstrate a beneﬁ  cial eﬀ  ect of the 
NSAIDs, either rofecoxib or naproxen, or more recently 
the amyloid-lowering NSAID, tarenﬂ   urbil, on the 
progression of AD [22,23]. Th   ese negative results do not, 
however, exclude the possibility that at a diﬀ  erent dose, at 
an earlier stage of the disease, or in a subgroup of patients 
(perhaps deﬁ   ned by genetic factors and PBMC [peri-
pheral blood mononuclear cell] production of inﬂ  am-
matory markers), these drugs may show beneﬁ  t.  Th  e 
ﬁ  nding by van Exel and colleagues [5] of elevations in 
pro inﬂ   ammatory cytokine production during early 
middle-age in persons with a family history of AD also 
suggests the possibility that a longer period of anti-
inﬂ  ammatory intervention may have yielded a diﬀ  erent 
result. In addition, their observation of higher blood 
pressures in this at-risk group implies that vascular risk 
factors may act in concert with increased inﬂ  ammation 
to enhance the risk for AD; hence, their potential 
synergistic interaction needs to be considered in future 
clinical trials.
In summary, this study adds to the growing body of 
evidence linking inﬂ  ammatory and vascular mechanisms 
to AD risk and provides some biological insights into the 
known increase in AD risk associated with a positive 
family history. It is premature to make clinical 
recommendations based on this study alone, but if these 
results can be extended to include incident AD and 
validated in other cohorts, they may help reﬁ  ne  risk 
prediction. Th  ey may also help identify future ‘environ-
mental’ primary or secondary prevention targets, both 
vascular and inﬂ   ammatory, for people with genetic 
susceptibility to AD. Furthermore, these data suggest that 
studies of anti-inﬂ  ammatory interventions might be best 
undertaken in subgroups at highest risk of AD, perhaps 
persons with a positive family history, at least one APOE 
ε4 allele, and documented mild cognitive impairment. 
Such trials should plan to carefully document the genetic, 
vascular risk factor, and inﬂ  ammatory status of subjects 
to identify whether the putative therapies could be 
beneﬁ  cial in selected subgroups.
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